A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Trial Profile

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 09 Apr 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 20 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top